Vor Bio to Participate in the Goldman Sachs Healthcare Conference
Monday, June 5, 2023 1 min read
Key Takeaway: Vor Bio, a clinical-stage cell and genome engineering company, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference. Scheduled for June 12, 2023, the event will include a fireside chat and in-person investor meetings. The company focuses on developing targeted therapies for blood cancers through innovative genome engineering techniques. Live coverage of the chat will be available on their investor website.
Market Sentiment Analysis
POSITIVE FACTORS
Vor Bio is participating in a high-profile Goldman Sachs conference.
The company aims to advance therapies for patients with blood cancers.
1x1 investor meetings may enhance investor engagement and funding opportunities.
Full Press Release Details
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sachs 44th Annual Global Healthcare Conference.
Goldman Sachs 44th Annual Global Healthcare Conference
Fireside Chat: Monday, June 12, 2023 at 8:00am PT
Location: Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Tags
Frequently Asked Questions
When is Vor Bio's fireside chat at the conference?
The fireside chat is on June 12, 2023, at 8:00 AM PT.
Where is the Goldman Sachs conference held?
The conference takes place at Waldorf Astoria Monarch Beach Resort, CA.
How can I access the fireside chat replay?
The replay will be available on Vor Bio's investor website.
What is Vor Bio's focus in healthcare?
Vor Bio focuses on engineering stem cells for blood cancer therapies.
What type of company is Vor Bio?
Vor Bio is a clinical-stage cell and genome engineering firm.